Oxidative stress events and neuronal dysfunction in alzheimer’s disease: Focus on APE1/ref-1-mediated survival strategies

Free Radicals in Human Health and Disease

Volumn , Issue , 2015, Pages 175-207

  Kaur, Navrattan ^a   Sarkar, Bibekananda ^a   Mittal, Sunil ^a   Dhiman, Monisha ^a   Taglialatela, Gulio ^b   Perez Polo, Regino J ^b   Mantha, Anil K ^a  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer s disease; Amyloid beta; APE1 Ref 1; Mitochondria; Oxidative stress; Phytochemicals

Indexed keywords

EID: 84927570667     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-81-322-2035-0_13     Document Type: Chapter

References (246)

1. Stelzmann RA, Norman Schnitzlein H, Reed Murtagh F (1995) An English translation of Alzheimer’s 1907 paper, “Über eine eigenartige Erkankung der Hirnrinde”. Clin Anat 8(6):429–431
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580): 353–356
3. Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1- 42 are potent central nervous system neurotoxins. Proc Natl Acad Sci 95(11):6448–6453
4. Zhu X, Raina AK, Lee HG et al (2004) Oxidative stress signalling in Alzheimer’s disease. Brain Res 1000(1):32–39
5. Leuner K, Muller WE, Reichert AS (2012) From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer’s disease. Mol Neurobiol 46(1): 186–193
6. Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 20(2):S265–S279
7. Clark TA, Lee HP, Rolston RK et al (2010) Oxidative stress and its implications for future treatments and management of Alzheimer disease. Int J Biomed Sci 6(3):225–227
8. Schriner SE, Linford NJ, Martin GM et al (2005) Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308(5730):1909–1911
9. Behl C, Davis JB, Lesley R et al (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77(6):817–827
10. Hensley K, Carney J, Mattson M et al (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci 91(8):3270–3274
11. Kadowaki H, Nishitoh H, Urano F et al (2005) Amyloid ß induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 12(1):19–24
12. Manczak M, Reddy PH (2012) Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease. Hum Mol Genet 21(23):5131–5146
13. Reddy PH (2006) Amyloid precursor proteinmediated free radicals and oxidative damage: implications for the development and progression of Alzheimer’s disease. J Neurochem 96(1):1–13
14. de la Monte SM, Luong T, Neely TR et al (2000) Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease. Lab Invest 80(8):1323–1335
15. Yang JL, Weissman L, Bohr VA et al (2008) Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair 7(7):1110–1120
16. Hegde ML, Mantha AK, Hazra TK et al (2012) Oxidative genome damage and its repair: implications in aging and neurodegenerative diseases. Mech Ageing Dev 133(4):157–168
17. Mantha AK, Sarkar B, Tell G (2013) A short review on the implications of base excision repair pathway for neurons: relevance to neurodegenerative diseases. Mitochondrion. doi: 10.1016/j.mito.2013.10.007
18. Bhakat KK, Mantha AK, Mitra S (2009) Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid Redox Signal 11(3):621–638
19. Xanthoudakis S, Curran T (1992) Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J 11(2):653
20. Marcon G, Tell G, Perrone L et al (2009) APE1/Ref-1 in Alzheimer’s disease: an immunohistochemical study. Neurosci Lett 466(3):124–127
21. Li M, Vascotto C, Xu S et al (2012) Human AP endonuclease/redox factor APE1/ref-1 modulates mitochondrial function after oxidative stress by regulating the transcriptional activity of NRF1. Free Radic Biol Med 53(2):237–248
22. Singh-Gupta V, Zhang H, Yunker CK et al (2010) Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy. Pharm Res 27(6):1115–1127
23. Silva JP, Gomes AC, Coutinho OP (2008) Oxidative DNA damage protection and repair by polyphenolic compounds in PC12 cells. Eur J Pharmacol 601(1–3):50–60
24. Yang IK, Heffron SE et al (2005) Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther 4(12):1923–1935
25. Takalo M, Salminen A, Soininen H et al (2013) Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am J Neurodegener Dis 2(1):1–14
26. Soto C, Kindy MS, Baumann M et al (1996) Inhibition of Alzheimer’s amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys Res Commun 226(3):672–680
27. Wimo A, Jonsson L, Winblad B (2006) An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21(3):175–181
28. Irvine GB, El-Agnaf OM, Shankar GM et al (2008) Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases. Mol Med 14(7–8):451
29. Thies W, Bleiler L (2011) 2011 Alzheimer’s disease facts and figures. Alzheimers Dement 7(2):208–244
30. Roses M, Allen D (1996) Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med 47(1):387–400
31. Saunders A, Strittmatter W, Schmechel D et al (1993) Association of apolipoprotein E allele Є4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43(8):1467–1467
32. Chapuis J, Hansmannel F, Gistelinck M et al (2013) Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry. doi: 10.1038/mp.2013.1
33. Hollingworth P, Harold D, Sims R et al (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43(5):429–435
34. Lambert JC, Heath S, Even G et al (2009) Genomewide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41(10):1094–1099
35. Wei YH, Lee HC (2002) Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp Biol Med 227(9):671–682
36. Reddy PH, Tripathi R, Troung Q et al (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 1822(5):639–649
37. Manczak M, Calkins MJ, Reddy PH (2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Hum Mol Genet 20(13):2495–2509
38. Guo L, Du H, Yan S et al (2013) Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimer’s neurons. PLoS One 8(1):e54914
39. Wilcock DM, Griffi n WS (2013) Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation 10:84
40. Tan MS, Yu JT, Tan L (2013) Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease. Trends Mol Med 19(10):594–603
41. Schellenberg GD, Montine TJ (2012) The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol 124(3):305–323
42. Anttila T, Helkala EL, Viitanen M et al (2004) Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ 329(7465):539
43. Ott A, Slooter AJ, Hofman A et al (1998) Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam Study. Lancet 351(9119):1840–1843
44. Launer LJ, Ross GW, Petrovitch H et al (2000) Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21(1):49–55
45. Whitmer RA, Gustafson DR, Barrett-Connor E et al (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71(14):1057–1064
46. Kivipelto M, Ngandu T, Fratiglioni L et al (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62(10):1556–1560
47. Solomon A, Kareholt I, Ngandu T et al (2007) Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68(10):751–756
48. Solomon A, Kivipelto M, Wolozin B et al (2009) Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord 28(1):75–80
49. Haag MD, Hofman A, Koudstaal PJ et al (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80(1):13–17
50. Huang TL, Zandi PP, Tucker KL et al (2005) Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 65(9):1409–1414
51. Laitinen MH, Ngandu T, Rovio S et al (2006) Fat intake at midlife and risk of dementia and Alzheimer’s disease: a population-based study. Dement Geriatr Cogn Disord 22(1):99–107
52. Povova J, Ambroz P, Bar M et al (2012) Epidemiological of and risk factors for Alzheimer’s disease: a review. Biomed Pap 156(2):108–114
53. Xu W, Qiu C, Gatz M et al (2009) Mid- and late-life diabetes in relation to the risk of dementia: a population- based twin study. Diabetes 58(1):71–77
54. Crawford FC, Vanderploeg RD, Freeman MJ et al (2002) APOE genotype infl uences acquisition and recall following traumatic brain injury. Neurology 58(7):1115–1118
55. Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3):303–308
56. Salminen A, Kaarniranta K, Kauppinen A et al (2013) Impaired autophagy and APP processing in Alzheimer’s disease: the potential role of Beclin 1 interactome. Prog Neurobiol 106–107:33–54
57. Pickford F, Masliah E, Britschgi M et al (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Investig 118(6):2190–2199
58. Cai Z, Yan LJ (2013) Rapamycin, Autophagy, and Alzheimer’s disease. J Biochem Pharmacol Res 1(2):84–90
59. Xue Z, Zhang S, Huang L et al (2013) Upexpression of Beclin-1-dependent autophagy protects against beta-amyloid-induced cell injury in PC12 cells. J Mol Neurosci 51(1):180–186
60. Meda L, Baron P, Scarlato G (2001) Glial activation in Alzheimer’s disease: the role of Abeta and its associated proteins. Neurobiol Aging 22(6):885–893
61. Strohmeyer R, Shen Y, Rogers J (2000) Detection of complement alternative pathway mRNA and proteins in the Alzheimer’s disease brain. Mol Brain Res 81(1):7–18
62. Webster S, Lue LF, Brachova L et al (1997) Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer’s disease. Neurobiol Aging 18(4):415–421
63. Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer’s disease, role of cytokines. Sci World J 2012:756357
64. Sinha S, Anderson JP, Barbour R et al (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402(6761):537–540
65. Rossner S, Lange-Dohna C, Zeitschel U et al (2005) Alzheimer’s disease beta-secretase BACE1 is not a neuron-specific enzyme. J Neurochem 92(2): 226–234
66. Bourne KZ, Ferrari DC, Lange-Dohna C et al (2007) Differential regulation of BACE1 promoter activity by nuclear factor-κB in neurons and glia upon exposure to β-amyloid peptides. J Neurosci Res 85(6):1194–1204
67. Barron AM, Verdile G, Martins RN (2006) The role of gonadotropins in Alzheimer’s disease: potential neurodegenerative mechanisms. Endocrine 29(2):257–269
68. Casadesus G, Milliken EL, Webber KM et al (2007) Increases in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol 269(1–2):107–111
69. Ziegler SG, Thornton JE (2010) Low luteinizing hormone enhances spatial memory and has protective effects on memory loss in rats. Horm Behav 58(5):705–713
70. Rosario ER, Carroll JC, Pike CJ (2012) Evaluation of the effects of testosterone and luteinizing hormone on regulation of beta-amyloid in male 3xTg-AD mice. Brain Res 1466:137–145
71. Dreses-Werringloer U, Bhuiyan M, Zhao Y et al (2009) Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the lateonset alzheimer brain. Int J Med Microbiol 299(3):187–201
72. Itzhaki RF, Wozniak MA, Appelt DM et al (2004) Infiltration of the brain by pathogens causes Alzheimer’s disease. Neurobiol Aging 25(5):619–627
73. Stein SMJ, Smith C et al (2012) Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimers Dement 8(3):196–203
74. Li W, Yu J, Liu Y et al (2013) Elevation of brain magnesium prevents and reverses cognitive defi cits and synaptic loss in Alzheimer’s disease mouse model. J Neurosci 33(19):8423–8441
75. Andrasi E, Pali N, Molnar Z et al (2005) Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis 7(4):273–284
76. Zapatero MD, Garcia de Jalon A, Pascual F et al (1995) Serum aluminum levels in Alzheimer’s disease and other senile dementias. Biol Trace Elem Res 47(1–3):235–240
77. Brenner S (2013) Aluminum may mediate Alzheimer’s disease through liver toxicity, with aberrant hepatic synthesis of ceruloplasmin and ATPase7B, the resultant excess free copper causing brain oxidation, beta-amyloid aggregation and Alzheimer disease. Med Hypotheses 80(3):326–327
78. Davenward S, Bentham P, Wright J et al (2013) Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease. J Alzheimers Dis 33(2):423–430
79. Li YY, Chen T, Wan Y et al (2012) Lead exposure in pheochromocytoma cells induces persistent changes in amyloid precursor protein gene methylation patterns. Environ Toxicol 27(8):495–502
80. Gu H, Robison G, Hong L et al (2012) Increased beta-amyloid deposition in Tg-SWDI transgenic mouse brain following in vivo lead exposure. Toxicol Lett 213(2):211–219
81. Zhu HL, Meng SR, Fan JB et al (2011) Fibrillization of human tau is accelerated by exposure to lead via interaction with His-330 and His-362. PLoS One 6(9):e25020
82. Brewer GJ (2009) The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer’s disease. J Am Coll Nutr 28(3):238–242
83. Kim CH, Yoo YM (2013) Altered APP carboxylterminal processing under ferrous iron treatment in PC12 cells. Korean J Physiol Pharmacol 17(3):189–195
84. Reese LC, Laezza F, Woltjer R et al (2011) Dysregulated phosphorylation of Ca2+/calmodulindependent protein kinase II-a in the hippocampus of subjects with mild cognitive impairment and Alzheimer’s disease. J Neurochem 119(4):791–804
85. Bjorklund NL, Sadagoparamanujam VM, Taglialatela G (2012) Selective, quantitative measurement of releasable synaptic zinc in human autopsy hippocampal brain tissue from Alzheimer’s disease patients. J Neurosci Methods 203(1):146–151
86. Bjorklund NL, Reese LC, Sadagoparamanujam V et al (2012) Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer’s disease neuropathology. Mol Neurodegener 7(1):1–13
87. Wang WT, Zheng W, Zhao BL et al (2010) Zinc overload enhances APP cleavage and Abeta deposition in the Alzheimer mouse brain. PLoS One 5(12):e15349
88. Calderon-Garciduenas L, Reed W, Maronpot RR et al (2004) Brain inflammation and Alzheimer’slike pathology in individuals exposed to severe air pollution. Toxicol Pathol 32(6):650–658
89. Moulton PV, Yang W (2012) Air pollution, oxidative stress, and Alzheimer’s disease. J Environ Public Health 2012:472751
90. Dorado-Martinez C, Paredes-Carbajal C, Mascher D et al (2001) Effects of different ozone doses on memory, motor activity and lipid peroxidation levels, in rats. Int J Neurosci 108(3–4):149–161
91. Rivas-Arancibia S, Guevara-Guzman R, Lopez-Vidal Y et al (2010) Oxidative stress caused by ozone exposure induces loss of brain repair in the hippocampus of adult rats. Toxicol Sci 113(1):187–197
92. Lesne S, Koh MT, Kotilinek L et al (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440(7082):352–357
93. Pham E, Crews L, Ubhi K et al (2010) Progressive accumulation of amyloid-beta oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 277(14):3051–3067
94. O’Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 34:185
95. Nunan J, Small DH (2000) Regulation of APP cleavage by α-, β-and γ-secretases. FEBS Lett 483(1):6–10
96. Pagani L, Eckert A (2011) Amyloid-Beta interaction with mitochondria. Int J Alzheimer Dis 2011:925050
97. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med 14(2):45–53
98. Yang GZ, Yang M, Lim Y et al (2012) Huntingtin associated protein 1 regulates trafficking of the amyloid precursor protein and modulates amyloid beta levels in neurons. J Neurochem 122(5):1010–1022
99. Zuchner T, Schliebs R, Perez-Polo JR (2005) Downregulation of muscarinic acetylcholine receptor M2 adversely affects the expression of Alzheimer’s disease-relevant genes and proteins. J Neurochem 95(1):20–32
100. Tonelli DDP, Mihailovich M, Di Cesare A et al (2004) Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. Nucleic Acids Res 32(5):1808–1817
101. Lublin AL, Gandy S (2010) Amyloid-β oligomers: possible roles as key neurotoxins in Alzheimer’s disease. Mt Sinai J Med 77(1):43–49
102. Murray MM, Bernstein SL, Nyugen V et al (2009) Amyloid β protein: Aβ40 inhibits Aβ42 oligomerization. J Am Chem Soc 131(18):6316–6317
103. Vassar R, Bennett BD, Babu-Khan S et al (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440):735–741
104. Hutton M (2004) Presenilin mutations associated with fronto-temporal dementia. Ann Neurol 55(5):604–606
105. Gandy S (2005) The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Inv 115(5):1121–1129
106. Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283(44):29639–29643
107. Billings LM, Oddo S, Green KN et al (2005) Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron 45(5):675–688
108. Cleary JP, Walsh DM, Hofmeister JJ et al (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8(1):79–84
109. Lauren J, Gimbel DA, Nygaard HB et al (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457(7233):1128–1132
110. Heinitz K, Beck M, Schliebs R et al (2006) Toxicity mediated by soluble oligomers of ß-amyloid (1–42) on cholinergic SN56. B5. G4 cells. J Neurochem 98(6):1930–1945
111. Joerchel S, Raap M, Bigl M et al (2008) Oligomeric β-amyloid (1-42) induces the expression of Alzheimer disease-relevant proteins in cholinergic SN56. B5. G4 cells as revealed by proteomic analysis. Int J Dev Neurosci 26(3):301–308
112. Kokubo H, Kayed R, Glabe CG et al (2009) Amyloid beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer associated genetic modification. Int J Alzheimer Dis 2009 pii: 689285
113. Shafrir Y, Durell SR, Anishkin A et al (2010) Betabarrel models of soluble amyloid beta oligomers and annular protofibrils. Proteins Struct Funct Bioinforma 78(16):3458–3472
114. Larson ME, Lesné SE (2012) Soluble Aβ oligomer production and toxicity. J Neurochem 120(s1):125–139
115. Swerdlow RH, Khan SM (2004) A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses 63(1):8–20
116. Trifunovic A, Wredenberg A, Falkenberg M et al (2004) Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429(6990):417–423
117. Caspersen C, Wang N, Yao J et al (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J 19(14):2040–2041
118. Larsson NG (2010) Somatic mitochondrial DNA mutations in mammalian aging. Annu Rev Biochem 79:683–706
119. Greaves LC, Turnbull DM (2009) Mitochondrial DNA mutations and ageing. Biochim Biophys Acta 1790(10):1015–1020
120. Tamagno E, Bardini P, Obbili A et al (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10(3):279–288
121. Tan JL, Li QX, Ciccotosto GD et al (2013) Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer’s disease amyloid precursor protein. PLoS One 8(4):e61246
122. Pigino G, Morfini G, Atagi Y et al (2009) Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci 106(14):5907–5912
123. Wang X, Perry G, Smith MA et al (2010) Amyloidbeta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons. Neurodegener Dis 7(1–3):56–59
124. Heller A, Brockhoff G, Goepferich A (2012) Targeting drugs to mitochondria. Eur J Pharm Biopharm 82(1):1–18
125. Wang X, Su B, Siedlak SL et al (2008) Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fi ssion/fusion proteins. Proc Natl Acad Sci 105(49):19318–19323
126. Lustbader JW, Cirilli M, Lin C et al (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science 304(5669):448–452
127. Du H, Yan SS (2010) Mitochondrial permeability transition pore in Alzheimer’s disease: cyclophilin D and amyloid beta. Biochim Biophys Acta 1802(1):198–204
128. Du H, Guo L, Fang F et al (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat Med 14(10):1097–1105
129. Du H, Guo L, Yan S et al (2010) Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc Natl Acad Sci 107(43):18670–18675
130. Ahn BH, Kim HS, Song S et al (2008) A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci 105(38):14447–14452
131. Kim SH, Lu HF, Alano CC (2011) Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One 6(3):e14731
132. Weir HJ, Murray TK, Kehoe PG et al (2012) CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer’s disease. PLoS One 7(11):e48225
133. Woo JA, Jung AR, Lakshmana MK et al (2012) Pivotal role of the RanBP9-cofilin pathway in Abetainduced apoptosis and neurodegeneration. Cell Death Differ 19(9):1413–1423
134. Kopeikina KJ, Carlson GA, Pitstick R et al (2011) Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain. Am J Pathol 179(4):2071–2082
135. Strosznajder JB, Czapski GA, Adamczyk A et al (2012) Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer’s disease. Mol Neurobiol 46(1):78–84
136. Kauppinen TM, Suh SW, Higashi Y et al (2011) Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid beta. J Neuroinflammation 8:152
137. Rossi MN, Carbone M, Mostocotto C et al (2009) Mitochondrial localization of PARP-1 requires interaction with mitofilin and is involved in the maintenance of mitochondrial DNA integrity. J Biol Chem 284(46):31616–31624
138. Turunc Bayrakdar E, Uyanikgil Y et al (2014) Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1-42)-induced rat model of Alzheimer’s disease. Free Radic Res 48(2):146–158
139. Altieri F, Grillo C, Maceroni M et al (2008) DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal 10(5):891–937
140. Bergamini CM, Gambetti S, Dondi A et al (2004) Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 10(14):1611–1626
141. Kruman II (2004) Why do neurons enter the cell cycle? Cell Cycle 3(6):767–771
142. Iyama T, Wilson DM 3rd (2013) DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst) 12(8):620–636
143. Crescenzi M, Soddu S, Tatò F (1995) Mitotic cycle reactivation in terminally differentiated cells by adenovirus infection. J Cell Physiol 162(1):26–35
144. Hegde M, Hazra T, Mitra S (2008) Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res 18(1):27–47
145. Fritz G (2000) Human APE/Ref-1 protein. Int J Biochem Cell Biol 32(9):925–929
146. Tell G, Zecca A, Pellizzari L, Spessotto P et al (2000) An ‘environment to nucleus’ signaling system operates in B lymphocytes: redox status modulates BSAP/Pax-5 activation through Ref-1 nuclear translocation. Nucleic Acids Res 28(5):1099–1105
147. Barnes T, Kim WC, Mantha AK et al (2009) Identification of Apurinic/apyrimidinic endonuclease 1 (APE1) as the endoribonuclease that cleaves c-myc mRNA. Nucleic Acids Res 37(12):3946–3958
148. Zaky A, Busso C, Izumi T et al (2008) Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage. Nucleic Acids Res 36(5):1555–1566
149. Tell G, Quadrifoglio F, Tiribelli C et al (2009) The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 11(3):601–619
150. Jiang Y, Guo C, Fishel ML et al (2009) Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair 8(11):1273–1282
151. Thakur S, Sarkar B, Cholia RP et al (2014) APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical modulation of its functions. Exp Mol Med 46:e106
152. Xanthoudakis S, Smeyne RJ, Wallace JD et al (1996) The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc Natl Acad Sci 93(17):8919–8923
153. Izumi T, Brown DB, Naidu C et al (2005) Two essential but distinct functions of the mammalian abasic endonuclease. Proc Natl Acad Sci U S A 102(16):5739–5743
154. Vasko MR, Guo C, Kelley MR (2005) The multifunctional DNA repair/redox enzyme Ape1/Ref-1 promotes survival of neurons after oxidative stress. DNA Repair 4(3):367–379
155. Davydov V, Hansen LA, Shackelford DA (2003) Is DNA repair compromised in Alzheimer’s disease? Neurobiol Aging 24(7):953–968
156. Tan Z, Shi L, Schreiber SS (2009) Differential expression of redox factor-1 associated with betaamyloid-mediated neurotoxicity. Open Neurosci J 3:26–34
157. Huang E, Qu D, Zhang Y et al (2010) The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death. Nat Cell Biol 12(6):563–571
158. Frosina G, Fortini P, Rossi O et al (1996) Two pathways for base excision repair in mammalian cells. J Biol Chem 271(16):9573–9578
159. Jacobs AL, Schär P (2012) DNA glycosylases: in DNA repair and beyond. Chromosoma 121(1):1–20
160. Hegde ML, Hegde PM, Rao K, Mitra S (2011) Oxidative genome damage and its repair in neurodegenerative diseases: function of transition metals as a double-edged sword. J Alzheimers Dis 24:183–198
161. Krokan H, Standal R, Slupphaug G (1997) DNA glycosylases in the base excision repair of DNA. Biochem J 325:1–16
162. Ariumi Y, Turelli P, Masutani M et al (2005) DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. J Virol 79(5):2973–2978
163. Strosznajder JB, Jesko H, Strosznajder RP (2000) Effect of amyloid beta peptide on poly(ADP-ribose) polymerase activity in adult and aged rat hippocampus. Acta Biochima Pol 47(3):847–854
164. Vidal AE, Boiteux S, Hickson ID et al (2001) XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J 20(22):6530–6539
165. Gredilla R, Bohr VA, Stevnsner T (2010) Mitochondrial DNA repair and association with aging–an update. Exp Gerontol 45(7):478–488
166. Bohr VA (2002) Repair of oxidative DNA damage in nuclear and mitochondrial DNA, and some changes with aging in mammalian cells. Free Radic Biol Med 32(9):804–812
167. Akbari M, Visnes T, Krokan HE et al (2008) Mitochondrial base excision repair of uracil and AP sites takes place by single-nucleotide insertion and long-patch DNA synthesis. DNA Repair (Amst) 7(4):605–616
168. Szczesny B, Tann AW, Longley MJ et al (2008) Long patch base excision repair in mammalian mitochondrial genomes. J Biol Chem 283(39):26349–26356
169. Alexeyev M, Shokolenko I, Wilson G et al (2013) The maintenance of mitochondrial DNA integrity—critical analysis and update. Cold Spring Harb Perspect Biol 5(5):a012641
170. Banerjee D, Mandal SM, Das A et al (2011) Preferential repair of oxidized base damage in the transcribed genes of mammalian cells. J Biol Chem 286(8):6006–6016
171. Chattopadhyay R, Wiederhold L, Szczesny B et al (2006) Identification and characterization of mitochondrial abasic (AP)-endonuclease in mammalian cells. Nucleic Acids Res 34(7):2067–2076
172. Lakshmipathy U, Campbell C (2000) Mitochondrial DNA ligase III function is independent of Xrcc1. Nucleic Acids Res 28(20):3880–3886
173. Tann AW, Boldogh I, Meiss G et al (2011) Apoptosis induced by persistent single-strand breaks in mitochondrial genome: critical role of exog (5'exo/endonuclease) in their repair. J Biol Chem 286(37):31975–31983
174. Liu P, Qian L, Sung J-S et al (2008) Removal of oxidative DNA damage via FEN1-dependent longpatch base excision repair in human cell mitochondria. Mol Cell Biol 28(16):4975–4987
175. Larsen E, Gran C, Sæther BE et al (2003) Proliferation failure and gamma radiation sensitivity of Fen1 null mutant mice at the blastocyst stage. Mol Cell Biol 23(15):5346–5353
176. Zheng L, Zhou M, Guo Z et al (2008) Human DNA2 is a mitochondrial nuclease/helicase for efficient processing of DNA replication and repair intermediates. Mol Cell 32(3):325–336
177. Walker L, Robson C, Black E et al (1993) Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol Cell Biol 13(9):5370–5376
178. Liu H, Colavitti R, Rovira II et al (2005) Redoxdependent transcriptional regulation. Circ Res 97(10):967–974
179. Xanthoudakis S, Miao G, Wang F et al (1992) Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J 11(9):3323–3335
180. Okazaki T, Ando K, Igarashi T et al (1992) Conserved mechanism of negative gene regulation by extracellular calcium. Parathyroid hormone gene versus atrial natriuretic polypeptide gene. J Clin Investig 89(4):1268–1273
181. Fuchs S, Philippe J, Corvol P et al (2003) Implication of Ref-1 in the repression of renin gene transcription by intracellular calcium. J Hypertens 21(2):327–335
182. Bhakat KK, Izumi T, Yang SH et al (2003) Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene. EMBO J 22(23):6299–6309
183. Tomecki R, Dziembowski A (2010) Novel endoribonucleases as central players in various pathways of eukaryotic RNA metabolism. RNA 16(9):1692–1724
184. Kim WC, Berquist BR, Chohan M et al (2011) Characterization of the endoribonuclease active site of human apurinic/apyrimidinic endonuclease 1. J Mol Biol 411(5):960–971
185. Ozaki M, Suzuki S, Irani K (2002) Redox factor-1/APE suppresses oxidative stress by inhibiting the rac1 GTPase. FASEB J 16(8):889–890
186. Angkeow P, Deshpande S, Qi B, Liu Y et al (2002) Redox factor-1: an extra-nuclear role in the regulation of endothelial oxidative stress and apoptosis. Cell Death Differ 9(7):717–725
187. Mantha AK, Dhiman M, Taglialatela G et al (2012) Proteomic study of amyloid beta (25-35) peptide exposure to neuronal cells: impact on APE1/Ref-1’s protein-protein interaction. J Neurosci Res 90(6):1230–1239
188. Das S, Das DK (2007) Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2(2):133–138
189. Rotondo S, Rajtar G, Manarini S et al (1998) Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol 123(8):1691–1699
190. Tsai SH, Lin-Shiau SY, Lin JK (1999) Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol 126(3):673–680
191. Belguendouz L, Fremont L, Linard A (1997) Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53(9):1347–1355
192. Orgogozo JM, Dartigues JF, Lafont S et al (1997) Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 153(3):185–192
193. Bastianetto S, Zheng WH, Quirion R (2000) Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol 131(4):711–720
194. Han YS, Zheng WH, Bastianetto S et al (2004) Neuroprotective effects of resveratrol against betaamyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 141(6):997–1005
195. Rigolio R, Miloso M, Nicolini G et al (2005) Resveratrol interference with the cell cycle protects human neuroblastoma SH-SY5Y cell from paclitaxel- induced apoptosis. Neurochem Int 46(3):205–211
196. Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloidbeta peptides. J Biol Chem 280(45):37377–37382
197. Jang MH, Piao XL, Kim HY et al (2007) Resveratrol oligomers from Vitis amurensis attenuate betaamyloid-induced oxidative stress in PC12 cells. Biol Pharm Bull 30(6):1130–1134
198. Tsai SK, Hung LM, Fu YT et al (2007) Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J Vasc Surg 46(2):346–353
199. Huang TC, Lu KT, Wo YY et al (2011) Resveratrol protects rats from Abeta-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One 6(12):e29102
200. Wang Q, Rowan MJ, Anwyl R (2004) Beta-amyloidmediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 24(27): 6049–6056
201. Albani D, Polito L, Batelli S et al (2009) The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by a-synuclein or amyloid-β (1-42) peptide. J Neurochem 110(5):1445–1456
202. Yamamori T, DeRicco J, Naqvi A et al (2010) SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res 38(3):832–845
203. Zaky A, Mohammad B, Moftah M et al (2013) Apurinic/apyrimidinic endonuclease 1 is a key modulator of aluminum-induced neuroinflammation. BMC Neurosci 14(1):1–12
204. Kunchandy E, Rao M (1990) Oxygen radical scavenging activity of curcumin. Int J Pharm 58(3):237–240
205. Zhang C, Browne A, Child D et al (2010) Curcumin decreases amyloid-ß peptide levels by attenuating the maturation of amyloid-ß precursor protein. J Biol Chem 285(37):28472–28480
206. Hegde M, Hegde P, Holthauzen L et al (2010) Specific inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron potential etiological linkage to neurodegenerative diseases. J Biol Chem 285(37):28812–28825
207. Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. J Alzheimers Dis 6(4):367–377
208. Scapagnini G, Colombrita C, Amadio M et al (2006) Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid Redox Signal 8(3–4):395–403
209. Lim G, Chu T, Yang F et al (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21(21):8370–8377
210. Yang F, Lim G, Begum A et al (2005) Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280(7):5892–5901
211. Kang SY, Lee KY, Park MJ et al (2003) Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice. Neurobiol Learn Mem 79(1):11–18
212. Shiomi K, Hatano H, Morimoto H et al (2007) Decursin and decursinol angelate selectively inhibit NADH-fumarate reductase of Ascaris suum. Planta Med 73(14):1478–1481
213. Li L, Li W, Jung S-W et al (2011) Protective effects of decursin and decursinol angelate against amyloid β-protein-induced oxidative stress in the PC12 cell line: the role of Nrf2 and antioxidant enzymes. Biosci Biotechnol Biochem 75(3):434–442
214. Kang SY, Kim YC (2007) Decursinol and decursin protect primary cultured rat cortical cells from glutamate-induced neurotoxicity. J Pharm Pharmacol 59(6):863–870
215. Li L, Du JK, Zou LY et al (2013) Decursin isolated from Angelica gigas Nakai Rescues PC12 cells from amyloid beta-protein-induced neurotoxicity through Nrf2-mediated upregulation of heme oxygenase-1: potential roles of MAPK. Evid Based Complement Alternat Med 2013:467245
216. Anderson RL, Wolf WJ (1995) Compositional changes in trypsin inhibitors, phytic acid, saponins and isoflavones related to soybean processing. J Nutr 125(3 Suppl):581S–588S
217. Ding J, Yu HL, Ma WW et al (2013) Soy isoflavone attenuates brain mitochondrial oxidative stress induced by beta-amyloid peptides 1-42 injection in lateral cerebral ventricle. J Neurosci Res 91(4):562–567
218. Lee Y-B, Lee HJ, Sohn HS (2005) Soy isoflavones and cognitive function. J Nutr Biochem 16(11):641–649
219. Bagheri M, Joghataei MT, Mohseni S et al (2011) Genistein ameliorates learning and memory deficits in amyloid beta(1-40) rat model of Alzheimer’s disease. Neurobiol Learn Mem 95(3):270–276
220. Ding BJ, Ma WW, He LL et al (2011) Soybean isoflavone alleviates beta-amyloid 1-42 induced inflammatory response to improve learning and memory ability by down regulation of Toll-like receptor 4 expression and nuclear factor-kappaB activity in rats. Int J Dev Neurosci 29(5):537–542
221. Hirohata M, Ono K, Takasaki J et al (2012) Antiamyloidogenic effects of soybean isoflavones in vitro: fluorescence spectroscopy demonstrating direct binding to Abeta monomers, oligomers and fibrils. Biochim Biophys Acta 1822(8):1316–1324
222. Luo S, Lan T, Liao W et al (2012) Genistein inhibits Abeta(25-35)-induced neurotoxicity in PC12 cells via PKC signaling pathway. Neurochem Res 37(12):2787–2794
223. Okumura N, Yoshida H, Nishimura Y et al (2012) Genistein downregulates presenilin 1 and ubiquilin 1 expression. Mol Med Rep 5(2):559–561
224. Katiyar SK, Agarwal R, Wang ZY et al (1992) (–)-Epigallocatechin-3-gallate in Camellia sinensis leaves from Himalayan region of Sikkim: inhibitory effects against biochemical events and tumor initiation in Sencar mouse skin. Nutr Cancer 18(1):73–83
225. Weinreb O, Amit T, Mandel S et al (2009) Neuroprotective molecular mechanisms of (-)-epigallocatechin- 3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 4(4):283–296
226. Zaveri NT (2006) Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 78(18):2073–2080
227. Hu G, Bidel S, Jousilahti P et al (2007) Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord 22(15):2242–2248
228. Mandel S, Amit T, Kalfon L et al (2008) Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis 15(2):211–222
229. Rezai-Zadeh K, Shytle D, Sun N et al (2005) Green tea Epigallocatechin-3-Gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25(38):8807–8814
230. Dragicevic N, Smith A, Lin X et al (2011) Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer’s amyloid-induced mitochondrial dysfunction. J Alzheimers Dis 26(3):507–521
231. Bieschke J, Russ J, Friedrich RP et al (2010) EGCG remodels mature a-synuclein and amyloid-ß fibrils and reduces cellular toxicity. Proc Natl Acad Sci 107(17):7710–7715
232. Lee JW, Lee YK, Ban JO et al (2009) Green tea (-)-epigallocatechin-3-gallate inhibits ß-amyloidinduced cognitive dysfunction through modifi cation of secretase activity via inhibition of ERK and NF-κB pathways in mice. J Nutr 139(10):1987–1993
233. Carta A, Calvani M, Bravi D et al (1993) Acetyl-l-Carnitine and Alzheimer’s disease: pharmacological considerations beyond the cholinergic spherea. Ann N Y Acad Sci 695(1):324–326
234. Hagen TM, Ingersoll RT, Wehr CM et al (1998) Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci 95(16):9562–9566
235. Calabrese V, Ravagna A, Colombrita C et al (2005) Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res 79(4):509–521
236. Taglialatela G, Angelucci L, Ramacci M et al (1991) Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor. Dev Brain Res 59(2):221–230
237. Pettegrew J, Levine J, McClure R (2000) Acetyl-Lcarnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry 5(6):616–632
238. Epis R, Marcello E, Gardoni F et al (2008) Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. Eur J Pharmacol 597(1):51–56
239. Abdul HM, Calabrese V, Calvani M et al (2006) Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1–42-mediated oxidative stress and neurotoxicity: Implications for Alzheimer’s disease. J Neurosci Res 84(2):398–408
240. Cheung WMW, Hui WS, Chu PWK et al (2000) Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells. FEBS Lett 486(3):291–296
241. Pillai TG, Salvi VP, Maurya DK et al (2006) Prevention of radiation-induced damages by aqueous extract of Ganoderma lucidum occurring in southern parts of India. Curr Sci 91(3): 341–347
242. Yueping Z, Hua Y, Li L et al (2008) Effects of Ganoderma Lucidum polysaccharides on caspase-3 and FasL expressions in the hippocampus of Alzheimer disease model rats [J]. Chin J Histochem Cytochem 5:016
243. Pinweha S, Wanikiat P, Sanvarinda Y et al (2008) The signaling cascades of Ganoderma lucidum extracts in stimulating non-amyloidogenic protein secretion in human neuroblastoma SH-SY5Y cell lines. Neurosci Lett 448(1):62–66
244. Sudheesh N, Ajith T, Janardhanan K (2009) Ganoderma lucidum (Fr.) P. Karst enhances activities of heart mitochondrial enzymes and respiratory chain complexes in the aged rat. Biogerontology 10(5):627–636
245. Ajith T, Sudheesh N, Roshny D et al (2009) Effect of Ganoderma lucidum on the activities of mitochondrial dehydrogenases and complex I and II of electron transport chain in the brain of aged rats. Exp Gerontol 44(3):219–223
246. Phan CW, David P, Naidu M et al (2013) Neurite outgrowth stimulatory effects of culinary-medicinal mushrooms and their toxicity assessment using differentiating Neuro-2a and embryonic fibroblast BALB/3T3. BMC Complement Altern Med 13(1):261